Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-9,page-paged-9,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.5.0,vc_responsive

CLIENT NEWS

 

 

  • Imcyse SA: Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
    www.imcyse.com
  • XPhyto announces psychedelic pharmaceutical production agreement
    www.xphyto.com
  • CENTOGENE GmbH: CENTOGENE eröffnet Walk-In-Corona-Testzentrum am Flughafen Köln / Bonn
    www.centogene.com
  • CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP® Technology in anti-tumor cell therapies
    www.cevec.com
  • CureVac and Rentschler Biopharma Ramp up Manufacturing of COVID-19 Vaccine, CVnCoV
    www.rentschler-biopharma.com
  • AiCuris changes its legal form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG
    www.aicuris.com
  • RedHill Biopharma Announces Positive DSMB Futility Review for Phase 2/3 COVID-19 Study of Opaganib
    www.redhillbio.com
  • Marinomed Biotech AG announces preliminary revenues and confirms outlook for 2020
    www.marinomed.com
  • RedHill Biopharma Further Expands Opaganib Manufacturing Capacity for COVID-19 with Cosmo Pharmaceuticals
    www.redhillbio.com
  • XPhyto announces drug formulation strategy and 2021 milestones
    www.xphyto.com